Major Depressive Disorder With Mixed Features - Extension (RESOLVE3)

This study has been completed.
Information provided by (Responsible Party):
Sunovion Identifier:
First received: August 23, 2011
Last updated: January 23, 2014
Last verified: January 2014

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.

Condition Intervention Phase
Major Depressive Disorder
Drug: Lurasidone
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features

Resource links provided by NLM:

Further study details as provided by Sunovion:

Primary Outcome Measures:
  • SAEs, AEs, Discontinuations due to SAEs and AEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
    Proportion of subjects with adverse events (AEs) and serious adverse events (SAEs) Discontinuations due to AEs and SAEs Change in movement disorders, as assessed by the Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS), and Simpson-Angus Rating Scale (SARS) Change in sexual functioning, as assessed by the Changes in Sexual Functioning Questionnaire (CSFQ).

Secondary Outcome Measures:
  • MADRS [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
    Mean change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total scores Proportion of subjects who achieve a response, defined as ≥ 50% reduction from double-blind baseline on the MADRS total score Proportion of subjects who achieve remission, defined as a MADRS total score of ≤ 12

Enrollment: 48
Study Start Date: September 2011
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lurasidone 20, 40, 60 mg
Lurasidone 20, 40, or 60 mg/day flexibly dosed
Drug: Lurasidone
Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
Other Name: Latuda


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.

Subject has completed 6 weeks of treatment in Study D1050304 or Study D1050305. Subject is judged by the Investigator to be suitable for participation in a 12-week clinical trial involving open-label lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator.

Exclusion Criteria:

Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of evaluation) at baseline (Day 43 in Study D1050304 or D1050305).

Subject is considered by the Investigator to be at imminent risk of suicide or injury to self, others, or property.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01423253

United States, Alabama
Birmingham Psychiatry Pharmaceutical Studies, Inc
Birmingham, Alabama, United States, 35226
United States, California
Synergy Clinical Research Center
Escondido, California, United States, 92025
Collaborative Neuro Science Network, Inc.
Garden Grove, California, United States, 92845
Stanford -VA Palo Alto Health Care System
Palo Alto, California, United States, 94304
Artemis Institute for Clinical Research
San Diego, California, United States, 92123
United States, Florida
Florida Clinical Research Center, LLC
Sarasota, Florida, United States, 34201
United States, Massachusetts
Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders
Boston, Massachusetts, United States, 02114
United States, Missouri
St. Charles Psychiatric Associates/Midwest Research Group
St. Charles, Missouri, United States, 63301
United States, New York
Village Clinical Research Inc.
New York, New York, United States, 10003
Finger Lakes Clinical Research
Rochester, New York, United States, 14618
Behavioral Medical Research of Staten Island
Staten Island, New York, United States, 10305
United States, North Carolina
Psychiatry and Behavioral Sciences, Duke
Durham, North Carolina, United States, 27705
United States, Ohio
Midwest Clinical Research Center
Dayton, Ohio, United States, 45408
United States, Pennsylvania
CRI Worldwide - Kirkbride
Philadelphia, Pennsylvania, United States, 19139
United States, Texas
Dept. of Psychiatry, UT Southwestern Medical Center
Dallas, Texas, United States, 75390-8849
FutureSearch Trials of Dallas, LP
Dallas, Texas, United States, 75231
Grayline Clinical Drug Trials
Wichita Falls, Texas, United States, 76309
Sponsors and Collaborators
Study Director: Medical Director, MD Sunovion
  More Information

No publications provided

Responsible Party: Sunovion Identifier: NCT01423253     History of Changes
Other Study ID Numbers: D1050306
Study First Received: August 23, 2011
Last Updated: January 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Sunovion:

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mental Disorders
Mood Disorders processed this record on October 06, 2015